precisionmedicineonline2d
Boehringer Ingelheim Strikes Deal to Use ExpressionEdits Tech in Two Gene Therapy Programs
ExpressionEdits' Genetic Syntax Engine platform is designed to enhance gene expression within gene therapies by restoring introns.
GEN2d
ExpressionEdits Partners with Boehringer to Enhance Gene Therapies with AI-Based Intron Design
Boehringer will leverage ExpressionEdits' Genetic Syntax Engine which generates optimized introns to increase protein expression.
ENDPOINTS NEWS4d
Boehringer In­gel­heim touts suc­cess in sec­ond Phase 3 lung fi­bro­sis tri­al
Boehringer Ingelheim said its experimental treatment for a chronic lung disease succeeded in a pivotal study, and it's taking ...
BioSpace4d
Boehringer Ingelheim’s Lung Fibrosis Drug Scores Second Late-Stage Win
Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...